Drugs / GSK-1070916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01118611 | Mar 2010 → Mar 2013 | cancer of unknown primary site | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK-1070916 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090479 ↗ |
| Known as | GSK1070916A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01118611 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Aurora-C inhibitor” CHEMBL1090479 ↗1“Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL1090479 ↗ |
| Modality | Small molecule | — CHEMBL1090479 ↗ |
| Route | Intravenous | “Patients receive Aurora B/C kinase inhibitor GSK1070916A IV over 1 hour once daily on days 1-5.” NCT01118611 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL1090479 ↗ |
| Target | AURKC | “Serine/threonine-protein kinase Aurora-C inhibitor” CHEMBL1090479 ↗ |